Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
There are concerns about neutralizing antibodies’ (NAbs’) potency against severe acute respiratory syndrome coronavirus 2 variants. Despite decreased NAb titers elicited by BNT162b2 vaccine against VOC202012/01 and 501Y.V2 strains, 28/29 healthcare workers (HCWs) had an NAb titer ≥1:10. In contrast, 6 months after coronavirus disease 2019 mild forms, only 9/15 (60%) of HCWs displayed detectable NAbs against 501Y.V2 strain.
Article activity feed
-
-
SciScore for 10.1101/2021.03.05.434089: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent for participation in this study was obtained from all participants. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Viral stocks were generated and titrated by the limiting dilution assay allowing calculation of tissue culture infective dose 50% (TCID50) after one passage of isolates on Vero cells. Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)Software and Algorithms Sentences Resources SARS-CoV-2 IgG immunoassay: SARS-CoV-2 anti-nucleocapsid (N) IgG were … SciScore for 10.1101/2021.03.05.434089: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent for participation in this study was obtained from all participants. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Viral stocks were generated and titrated by the limiting dilution assay allowing calculation of tissue culture infective dose 50% (TCID50) after one passage of isolates on Vero cells. Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)Software and Algorithms Sentences Resources SARS-CoV-2 IgG immunoassay: SARS-CoV-2 anti-nucleocapsid (N) IgG were determined using a commercially available immunoassay kit (Alinity SARS-CoV-2 IgG assay, Abbott Laboratories) according to the manufacturer’s instructions. Abbott Laboratoriessuggested: NoneStatistical analysis: Difference in distribution of NAb titer between UK strain or SA strain with the D614G strain was performed with a two-tailed Mann-Whitney-U test in GraphPad Prism 6.0. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of our work is that we were not able to assess potential cellular response differences against the three strains in the vaccinated or convalescent groups although it has been described generation of a robust CD4+ and CD8+ responses against the Wuhan ancestral strain[11]. The long-term evaluation regarding the lasting of NAb induced by vaccination is needed to assess the durability of protection against SARS-CoV-2 variants.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-